Opinion
Video
Balancing Efficacy and Quality of Life in Late-Line RRMM
Author(s):
Panelists discuss how balancing treatment effectiveness with quality of life in late-line multiple myeloma therapy requires a highly personalized approach, with patients and physicians collaboratively weighing factors such as potential for deeper or longer remissions against toxicity profiles, treatment logistics (inpatient vs. outpatient administration), impact on daily activities, financial toxicity, caregiver burden and individual patient goals, with many emphasizing that this calculus shifts as patients progress through treatment lines—often prioritizing aggressive approaches earlier while placing greater emphasis on maintaining functionality and meaningful life experiences in later treatment stages.
Video content above is prompted by the following:
- How do you balance treatment effectiveness with quality of life considerations in late-line therapy?
